Atorvastatin Calcium Hydrate

阿托伐他汀钙水合物

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameAtorvastatin Calcium Hydrate
Drug Alias NameatorvastatineAtorvastatin calciumatorvastatinumatorvastatinaatovastatin +[25] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHMG-CoA reductase inhibitors
TargetsHMG-CoA reductase
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaCoronavirus Disease 2019 (COVID-19)Skin Melanoma +[97] 
Global Approved IndicationsHypercholesterolemiaHyperlipoproteinemia Type IICoronary Disease
Approved Indications in ChinaHypercholesterolemiaCoronary Disease
Original Approved Country/TerritoryUnited States
Original Approved Date1996/12/17
Country/TerritoryBelgiumCanadaUnited States +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesUpjohn IncMisr University For Science And TechnologyShahid Beheshti University Of Medical Sciences +[24] 
Inactive CompaniesUtah State UniversityViatrisUniversity of Toronto +[59] 
Active IndicationsHeterozygous familial hypercholesterolemiaSkin MelanomaSolid tumours +[38] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Contrast-induced nephropathyIschemic Stroke +[59] 

Other Information

ATC CodeC10AA05
Related LinksWikipediaDrugBankKEGG